Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

Analyzing Nano Drugs

Dec 12, 2013

FDA details efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

Super Oversight for Generics

Dec 12, 2013

OGD is under pressure to improve review operations.

Congress Revises Rules for Drug Compounding and Supply-Chain Security

Legislators agree on a limited bill affirming FDA authority over compounders while setting up a process for national drug tracking.
Dec 4, 2013

Legislators agree on a limited bill affirming FDA authority over compounders while setting up a process for national drug tracking.

Opioid Regulation Challenges FDA and Manufacturers

New policies and products seek to maintain access to pain medicines while curbing rampant abuse.
Dec 2, 2013

New policies and products seek to maintain access to pain medicines while curbing rampant abuse.

FDA Seeks Metrics to Define Drug Quality

Manufacturing standards are considered key to preventing drug recalls and shortages.
Nov 13, 2013

Manufacturing standards are considered key to preventing drug recalls and shortages.

FDA Promotes Personalized Medicine

Nov 8, 2013

FDA Promotes Personalized Medicine

Breakthrough Therapies Raise Manufacturing Issues

Nov 8, 2013

Breakthrough Therapies Raise Manufacturing Issues

FDA Moves to Curb Drug Shortages

Nov 8, 2013

FDA Moves to Curb Drug Shortages

Generic Drug Super Office Takes Shape

Nov 8, 2013

Generic Drug Super Office Takes Shape

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
10%
Protecting the supply chain
40%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here